Cohance Lifesciences Ltd.
NSE: COHANCECohance Lifesciences Ltd.: A 30-second snapshot
Cohance Lifesciences trades at Rs 425.30, down 57.28% over the past year and 59.06% below its 52-week high, sitting below both its 50-DMA (Rs 435.46) and 200-DMA (Rs 466.72). Five-year earnings contracted 89% against a 26.3% revenue decline, with ROE at 3.84% and a quality score of 10 relative to its pharma peer group. Trailing PE of 90.82 (forward PE 41.61) is the highest among the 6 peers tracked.
P/E
90.8
Forward P/E
41.6
ROE
+3.8%
Debt / Equity
9.93
Profit Margin
+7.9%
Div. Yield
—
5Y ROE > 15%
2/5
5Y FCF > 0
4/5
Quality
30/100
News
4 headlines · 0 positive · 0 negative
Global Indocyanine Green Market to Exceed USD 380 Million by 2031, Growing at a CAGR of 13.26% - Exclusive Insights by Arizton - PR Newswire UK
PR Newswire UK
Volumes spurt at Afcons Infrastructure Ltd counter - Business Standard
Business Standard
DSP Healthcare Fund - Direct Plan - CNBC TV18
CNBC TV18
Cohance Lifesciences - 10 Nifty 500 stocks plunge over 52-week highs. Do you own any? - economictimes.com
economictimes.com
Recent context
- ·News flow specific to Cohance was sparse this period: of the 4 headlines retrieved, 2 are keyword matches on unrelated companies (Afcons Infrastructure; a DSP mutual-fund product) and 1 is a generic global market-size report, leaving only 1 headline (an economictimes.com listicle on Nifty 500 stocks off their 52-week highs, published July 9, 2026) that references Cohance directly.
- ·Price action shows continued weakness rather than stabilization, with the 3-month change at -6.35% following the 12-month decline of 57.28%.
- ·Mean analyst rating of 2.78 across 9 analysts (1-5 scale, lower = more constructive) is the coverage figure available for this period.
Strengths
- +Free cash flow was positive in 4 of the last 5 years, per the persistence data.
- +RSI reads 44.34, in neutral territory rather than an extreme.
- +Forward PE of 41.61 is well below the trailing PE of 90.82, reflecting a lower expected earnings base priced into forward estimates.
- +Mean analyst rating of 2.78 across 9 analysts (1-5 scale, lower = more constructive) is tracked for the stock, with defined support levels at Rs 418.55, Rs 417.25 and Rs 403.40 from recent price action.
Weaknesses
- −Earnings declined 89% over 5 years against a 26.3% revenue decline; ROE is 3.84% and the quality score of 10 is the weakest in the observed peer set.
- −Price is down 57.28% over 1 year and 59.06% below the 52-week high, below both the 50-DMA and 200-DMA, with the 3-month change still negative at -6.35%.
- −Trailing PE of 90.82 ranks 6 of 6 (most expensive) in the peer group while quality score ranks 5 of 6.
- −ROE exceeded 15% in only 2 of the trailing 5 years and the consistency score is 39; debt trend is recorded as rising even though the current debt-to-equity level (~0.10x) is low.
Open questions
- ?What is driving the 89% five-year earnings decline relative to the smaller 26.3% revenue decline -- cost structure, one-off items, or both?
- ?Does the positive free cash flow in 4 of the last 5 years, set against the sharp earnings and ROE decline, reflect non-cash charges or a structural gap between cash generation and reported profitability?
- ?What operational or margin changes would be needed to close the gap between the current 90.82 trailing PE and the 41.61 forward PE?
- ?Given the debt trend is rising even though the absolute debt-to-equity level remains low (~0.10x), how is capital allocation and borrowing expected to evolve from here?
Peer comparison: Pharma
Ranks 5 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| COHANCE | Cohance Lifesciences Ltd.You're viewing | 90.8 | +3.8% | 10 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹425.30
SMA 50
₹435.46
SMA 200
₹466.72
RSI (14)
44.3 (neutral)
From 52w high
-59.1%
1Y return
-57.3%
3M return
-6.3%
50-DMA
Below
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highEarnings contracted 89% over 5 years against a smaller 26.3% revenue decline; ROE stands at 3.84% and the composite quality score is 10, the weakest fundamentals profile in the observed pharma peer set.
- highPrice is down 57.28% over the past year and 59.06% below its 52-week high, trading below both the 50-DMA (Rs 435.46) and 200-DMA (Rs 466.72); the 3-month change remains negative at -6.35%, showing no recent stabilization.
- mediumTrailing PE of 90.82 is the highest among the peer group (rank 6 of 6), while the quality score ranks 5 of 6 -- premium valuation alongside sub-median peer-relative quality. Forward PE of 41.61 implies the market is pricing a materially lower forward earnings base than trailing earnings would suggest.
- mediumROE exceeded 15% in only 2 of the trailing 5 years and the consistency score is 39; the debt trend is recorded as rising, though the underlying debt-to-equity level itself is low at roughly 0.10x (the raw Yahoo debtToEquity of 9.928 is percentage-scaled, i.e. 9.928/100).
- mediumOnly 4 news headlines were retrieved this run, and at least 2 are keyword collisions referencing unrelated companies (Afcons Infrastructure, a DSP mutual-fund product) rather than Cohance, with a 3rd a generic industry market-size report unrelated to the company. Only 1 headline substantively references Cohance. The 4-neutral sentiment tally should not be read as a signal given this.
Cross-section contradictions
- Free cash flow was positive in 4 of the last 5 years even as 5-year earnings fell 89% and ROE sits at 3.84% -- a divergence between cash generation and reported-profitability trends.
- The stock carries the highest trailing PE (90.82) in its pharma peer group while ranking 5 of 6 on quality score -- premium valuation paired with below-median peer-relative quality.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days